These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 15823761

  • 21. Anakinra treatment of patients with rheumatoid arthritis.
    Calabrese LH.
    Ann Pharmacother; 2002; 36(7-8):1204-9. PubMed ID: 12086555
    [Abstract] [Full Text] [Related]

  • 22. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 23. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, Emery P.
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [Abstract] [Full Text] [Related]

  • 24. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
    Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M.
    Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
    [Abstract] [Full Text] [Related]

  • 25. Biologics in rheumatoid arthritis.
    Sharma PK, Hota D, Pandhi P.
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [Abstract] [Full Text] [Related]

  • 26. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W, Jobanputra P, Barton P, Burls A.
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [Abstract] [Full Text] [Related]

  • 27. Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis.
    Garces K.
    Issues Emerg Health Technol; 2001 May; (16):1-4. PubMed ID: 11776280
    [Abstract] [Full Text] [Related]

  • 28. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.
    Kary S, Burmester GR.
    Int J Clin Pract; 2003 Apr; 57(3):231-4. PubMed ID: 12723729
    [Abstract] [Full Text] [Related]

  • 29. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.
    Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study Group.
    J Rheumatol; 2003 Feb; 30(2):225-31. PubMed ID: 12563672
    [Abstract] [Full Text] [Related]

  • 30. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
    Yazici Y, Erkan D, Paget SA.
    Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [Abstract] [Full Text] [Related]

  • 32. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.
    Bresnihan B, Cobby M.
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii22-8. PubMed ID: 12817092
    [Abstract] [Full Text] [Related]

  • 33. [Anakinra for therapy of rheumatoid arthritis].
    Tomoo T, Sumida T.
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
    [No Abstract] [Full Text] [Related]

  • 34. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
    Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA.
    Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
    [Abstract] [Full Text] [Related]

  • 35. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [Abstract] [Full Text] [Related]

  • 36. Examining the efficacy of biologic therapy: are there real differences?
    Fleischmann RM.
    J Rheumatol Suppl; 2002 Sep; 65():27-32. PubMed ID: 12236619
    [Abstract] [Full Text] [Related]

  • 37. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
    Schiff MH.
    Drugs; 2004 Sep; 64(22):2493-501. PubMed ID: 15516150
    [Abstract] [Full Text] [Related]

  • 38. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI.
    Scand J Rheumatol; 2009 Sep; 38(1):11-4. PubMed ID: 19191187
    [Abstract] [Full Text] [Related]

  • 39. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.
    Bresnihan B.
    Clin Exp Rheumatol; 2002 Sep; 20(5 Suppl 27):S32-4. PubMed ID: 14989427
    [Abstract] [Full Text] [Related]

  • 40. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.